Troy Puar1, Anouk van Berkel1, Martin Gotthardt1, Bas Havekes1, Ad R M M Hermus1, Jacques W M Lenders1, Wouter D van Marken Lichtenbelt1, Ying Xu1, Boudewijn Brans1, Henri J L M Timmers1. 1. Department of Internal Medicine (T.P., A.v.B., A.R.M.M.H., H.J.L.M.T.), Division of Endocrinology, Department of Radiology and Nuclear Medicine (M.G.), and Department of Internal Medicine (J.W.M.L.), Division of Vascular Medicine, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands; Department of Endocrinology (T.P.), Changi General Hospital, Singapore 529889, Singapore; Department of Internal Medicine (B.H.), Division of Endocrinology, and Department of Human Biology (W.D.v.M.L.), NUTRIM School for Nutrition, Toxicology, and Metabolism, and Department of Medical Imaging (B.B.), Division of Nuclear Medicine, Maastricht University Medical Centre, 6202 AZ Maastricht, The Netherlands; Department of Medicine and Institute of Clinical Chemistry and Laboratory Medicine (J.W.M.L.), University Hospital Carl Gustav Carus, 01307 Dresden, Germany; and Centre for Quantitative Medicine (Y.X.), Duke-National University Singapore Graduate Medical School, Singapore 169856, Singapore.
Abstract
CONTEXT: Patients with pheochromocytomas and paragangliomas (PGLs) may have brown adipose tissue (BAT) activation induced by catecholamine excess. (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET)/computed tomography (CT) can be used for the localization of both PGLs and BAT. It is unknown whether BAT is specifically affected by altered cellular energy metabolism in patients with SDHx- and VHL-related PGLs. OBJECTIVE: The objective of the study was to determine endocrine and paracrine effects of catecholamine excess on BAT activation in patients with PGLs as detected by (18)F-FDG PET/CT, taking into account genetic variation. DESIGN: Patients with PGLs who were fully genetically characterized underwent presurgical (18)F-FDG PET/CT imaging for tumor localization and to quantify BAT activation. SETTING: The study was conducted at a single Dutch tertiary referral center. PATIENTS AND INTERVENTION: Seventy-three patients, aged 52.4 ± 15.4 years, with a body mass index of 25.2 ± 4.1 kg/m(2), mean ± SD, were grouped into sporadic, cluster 1 (SDHx, VHL) and cluster 2 (RET, NF1, MAX) mutations. MAIN OUTCOME MEASURES: (18)F-FDG mean standard uptake values were assessed in predefined BAT locations, including perirenal fat. RESULTS: Twenty-one of 73 patients (28.8%) exhibited BAT activation. BAT activation was absent in all six patients with nonsecreting PGLs. No difference in (18)F-FDG uptake by perirenal fat on the side of the pheochromocytoma and the contralateral side was observed (mean standard uptake value of 0.80 vs 0.78, respectively, P = .42). The prevalence of BAT activation did not differ between sporadic (28.9%), cluster 1 (40.0%), and cluster 2 patients (15.4%, P= .36). CONCLUSION: Patients with PGLs exhibit a high prevalence of BAT activation on (18)F-FDG PET/CT. This is likely due to systemic catecholamine excess. BAT activation is not associated with specific germline mutations.
CONTEXT: Patients with pheochromocytomas and paragangliomas (PGLs) may have brown adipose tissue (BAT) activation induced by catecholamine excess. (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET)/computed tomography (CT) can be used for the localization of both PGLs and BAT. It is unknown whether BAT is specifically affected by altered cellular energy metabolism in patients with SDHx- and VHL-related PGLs. OBJECTIVE: The objective of the study was to determine endocrine and paracrine effects of catecholamine excess on BAT activation in patients with PGLs as detected by (18)F-FDG PET/CT, taking into account genetic variation. DESIGN:Patients with PGLs who were fully genetically characterized underwent presurgical (18)F-FDG PET/CT imaging for tumor localization and to quantify BAT activation. SETTING: The study was conducted at a single Dutch tertiary referral center. PATIENTS AND INTERVENTION: Seventy-three patients, aged 52.4 ± 15.4 years, with a body mass index of 25.2 ± 4.1 kg/m(2), mean ± SD, were grouped into sporadic, cluster 1 (SDHx, VHL) and cluster 2 (RET, NF1, MAX) mutations. MAIN OUTCOME MEASURES: (18)F-FDG mean standard uptake values were assessed in predefined BAT locations, including perirenal fat. RESULTS: Twenty-one of 73 patients (28.8%) exhibited BAT activation. BAT activation was absent in all six patients with nonsecreting PGLs. No difference in (18)F-FDG uptake by perirenal fat on the side of the pheochromocytoma and the contralateral side was observed (mean standard uptake value of 0.80 vs 0.78, respectively, P = .42). The prevalence of BAT activation did not differ between sporadic (28.9%), cluster 1 (40.0%), and cluster 2 patients (15.4%, P= .36). CONCLUSION:Patients with PGLs exhibit a high prevalence of BAT activation on (18)F-FDG PET/CT. This is likely due to systemic catecholamine excess. BAT activation is not associated with specific germline mutations.
Authors: Safaa H Hammoud; Ibrahim AlZaim; Yusra Al-Dhaheri; Ali H Eid; Ahmed F El-Yazbi Journal: Front Endocrinol (Lausanne) Date: 2021-08-02 Impact factor: 5.555
Authors: Zahraa Abdul Sater; Abhishek Jha; Ahmed Hamimi; Adel Mandl; Iris R Hartley; Sriram Gubbi; Mayank Patel; Melissa Gonzales; David Taïeb; Ali Cahid Civelek; Ahmed M Gharib; Sungyoung Auh; Alana E O'Mara; Karel Pacak; Aaron M Cypess Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958